drugset / Trial / NCT02838628

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

NCT02838628

Phase 2 Completed 168 enrolled Almirall, S.A. Athenex, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.

Timeline

Start
2016-04-11
Primary completion
2017-01-11
Completion
2017-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirbanibulin Small molecule 50 mg Topical

Indications